IQVIA Holdings Inc. $IQV Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 127,668 shares of the medical research company’s stock after acquiring an additional 7,578 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IQVIA were worth $28,778,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Alliancebernstein L.P. raised its holdings in shares of IQVIA by 1.2% during the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after acquiring an additional 41,643 shares during the last quarter. Boston Partners acquired a new stake in shares of IQVIA in the third quarter valued at approximately $676,698,000. Artisan Partners Limited Partnership grew its position in IQVIA by 4.9% in the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after acquiring an additional 161,085 shares during the period. Invesco Ltd. grew its position in IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after acquiring an additional 367,204 shares during the period. Finally, Nordea Investment Management AB grew its position in IQVIA by 12.3% in the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after acquiring an additional 253,759 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $175.80 on Wednesday. The business’s 50 day simple moving average is $170.31 and its 200-day simple moving average is $203.50. The firm has a market capitalization of $29.83 billion, a price-to-earnings ratio of 22.37, a price-to-earnings-growth ratio of 1.76 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday. JPMorgan Chase & Co. cut their price target on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Citigroup cut their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Finally, Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $226.63.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.